Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reblozyl in MDS with del5q (Phoenix)
NCT05924100Phase 2Recruiting
- Sponsor
- Qol-one
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of luspatercept in myelodysplastic syndrome (MDS), anemia, sponsored by Qol-one. Started Nov 2022; status: recruiting.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)anemia
Beyond the preview
Go deeper on NCT05924100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05924100.